Bench To Bedside
We develop novel therapeutic drugs by translating the ideas and discoveries in basic research.
Bedside To Bench
We perform R&D with the aim for tackling unmet medical needs.
Beyond Traditional Benchmark
We conduct drug development research based on evaluation
metrics that differ from traditional benchmarks.
We conduct drug development research based on evaluation metrics that differ from traditional benchmarks.
Borderless Translational Biology
We promote interdisciplinary collaboration across
different hospital departments and academic fields.
Bundling Transdisciplinary Branches
We coordinate the launch of new drugs in clinical trials by
working across various hospital departments and academic settings.
We coordinate the launch of new drugs in clinical trials by working across various hospital departments and academic settings.
Breeding Therapeutic Breakthroughs
We perform R&D with the attitude of constantly delivering
new knowledge in the world.
We perform R&D with the attitude of constantly delivering new knowledge in the world.
2023.10.27TopicsAt the general meeting of shareholders held on October 17, 2023, a resolution was passed to elect the following director.
Takashi Kiyoizumi, Director (U.S. Development) (New Appointment)
2023.10.27TopicsWe have received an investment from Innovation Kyoto 2021 Investment Limited Partnership with Kyoto University Innovation Capital Corporation (Kyoto iCAP) as a partner with unlimited liability.
With this investment, we will promote research and development of next-generation cancer immunotherapeutics and rare disease therapeutics (genetic diseases) with a focus on novel pain medications for further growth.
*Click here for press release by Kyoto iCAP (Japanese only)
2023.07.28TopicsWe have been selected by the Japan Agency for Medical Research and Development (AMED) for the FY2023 "Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Open Call)" (2nd round). Under this project, we will begin full-scale development of our product in the United States.
Title: Development of ENDOPIN, an oral analgesic that activates the descending pain suppression pathway
Click here to see the selected proposals. (Japanese only)
2023.04.18TopicsThe website of BTB Drug Development Research Center has been updated.
The company logo has been renewed.
2023.04.06NewsWe have received an investment from Kyogin Shining Future Support FundⅢfor SDGs Investment Limited Partnership (a fund jointly established by the Bank of Kyoto and Kyogin Lease & Capital Co., Ltd., a company under the Bank of Kyoto Group).
We will channel this investment toward promoting the R&D of novel drugs for the treatment of pain, next-generation immunotherapeutic drugs for cancer, and drugs for the treatment of rare diseases (genetic diseases) in order to spur the growth of our company.
*Click here for the press release by the Bank of Kyoto.
2023.03.28NewsThe R&D of next-generation immunotherapeutic drugs for cancer at Kyoto University has been approved as a Practical Research for Innovative Cancer Control for FY2023 by the Japan Agency for Medical Research and Development (AMED). We will continue to engage in R&D projects in collaboration with Kyoto University.
*Click here for a list of approved projects.
2023.03.22NewsWe participated in the 4th Kyoto University LifeScience Showcase @ San Diego 2023 as an academia-affiliated venture company and received the Best Presentation Award.
*Click here for the press release by Kyoto University.